CurrentEndo
Get Weekly

Topic · page 2 of 12

Lipids & metabolic liver disease

Lipid disorders and metabolic dysfunction-associated steatotic (fatty) liver disease, as published in the endocrine journals

Briefs 41–80 of 460 placed here, newest publication first

Briefs in Lipids & metabolic liver disease

Newest publication first

  1. Cardiovasc Diabetol

    Associations of cumulative exposure and dynamic trajectories of the combined atherogenic and frailty index with incident cardiometabolic multimorbidity: a longitudinal analysis based on the China Health and Retirement Longitudinal Study (CHARLS)

    Cohort study

  2. Diabetes Obes Metab

    Associations of PM 2 .5 and Its Constituents With the Dynamic and Accelerated Progression of Cardiovascular‐Kidney‐Metabolic Syndrome: The Gold‐Health Cohort

    Cohort study

  3. Diabetes Obes Metab

    Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9 ‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

    Meta-analysis

  4. BMJ Open Diabetes Res Care

    Reduced circulating Mig-6 levels are associated with dysglycemia in metabolic dysfunction associated steatotic liver disease (MASLD)

    Cross-sectional study

  5. Cardiovasc Diabetol

    Association between C-reactive protein-triglyceride glucose related indices and all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome

    Cohort study

  6. Cardiovasc Diabetol

    Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiovascular-liver-metabolic multimorbidity: a prospective cohort study from UK Biobank

    Cohort study

  7. Diabetes Obes Metab

    Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis

    Cohort study

  8. Cardiovasc Diabetol

    Associations of the combined C-reactive protein-triglyceride glucose index and frailty index in different dimensions with incident stroke among individuals with stages 0–3 cardiovascular-kidney-metabolic syndrome

    Cohort study

  9. Cardiovasc Diabetol

    Comparative prognostic value of TyG index and TyG-BMI for 90-day all-cause mortality in critically ill older adults with ASCVD: a machine learning analysis of the MIMIC-IV database

    Cohort study

  10. Diabetes Obes Metab

    Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts

    Cohort study

  11. Diabetes Obes Metab

    Large‐Scale Plasma Proteomics Improves Prediction of Major Adverse Liver Outcomes in Individuals With MASLD

    Cohort study

  12. Cardiovasc Diabetol

    Multi-omics uncovers the pleiotropic genetic mechanisms linking MASLD and cardiometabolic syndromes

    Research article

  13. Diabetes Metab

    Risk stratification of MASLD-related advanced fibrosis using a novel point-of-care device: the Hepatoscope

    Diagnostic or prognostic study

  14. Cardiovasc Diabetol

    Associations of nine insulin resistance-related indices with the incidence and progression of cardiovascular-liver-metabolic multimorbidity: a large prospective cohort study

    Cohort study

  15. Cardiovasc Diabetol

    The association between triglyceride glucose-frailty index and cardiometabolic multimorbidity among Chinese middle-aged and older adults: a national prospective cohort study

    Cohort study

  16. Diabetes Obes Metab

    High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

    Cross-sectional study

  17. Cardiovasc Diabetol

    Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies

    Cohort study

  18. Diabetes Obes Metab

    Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

    Cohort study

  19. Cardiovasc Diabetol

    LDL-C combined with Chinese visceral adiposity index as a risk stratification tool for cardiometabolic multimorbidity in middle-aged and older Chinese adults: a national prospective cohort study

    Cohort study

  20. Cardiovasc Diabetol

    Comprehensive evaluation of the triglyceride glucose index (TyG) and body roundness index (BRI) on cardiovascular disease risk prediction: a 9-year prospective cohort study in Chinese middle-aged and older adults

    Cohort study

  21. Diabetologia

    Oral glucose absorption is enhanced in early metabolic dysfunction-associated steatotic liver disease

    Mechanistic study

  22. Diabetes Obes Metab

    Cold‐Induced Lipidomic Remodelling Is Associated With Brown Adipose Tissue Mean Radiodensity in Humans

    Mechanistic study

  23. Diabetes Obes Metab

    Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5‐Year Korean Cohort Study

    Cohort study

  24. Cardiovasc Diabetol

    Cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index (CTI) versus the cholesterol, high-density lipoprotein, and glucose index (CHG) for incident hypertension prediction: a national cohort study

    Cohort study

  25. Diabetes Obes Metab

    Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials

    Meta-analysis

  26. Diabetes Obes Metab

    Risk Stratification of Chronic Kidney Disease in Adults Using Noninvasive Fibrosis Tests Based on the American Diabetes Association Algorithm

    Cohort study

  27. Cardiovasc Diabetol

    The prognostic significance of cholesterol, high-density lipoprotein and glucose (CHG) index in evaluating all-cause mortality risk in metabolic dysfunction-associated steatotic liver disease (MASLD) individuals: evidence from two cohort studies

    Cohort study

  28. Cardiovasc Diabetol

    The association between liver fat content and plasma metabolite profiles in fasting and postprandial states: an integration of a cohort study and a randomized controlled trial

    Randomized controlled trial

  29. Cardiovasc Diabetol

    Joint association of triglyceride-glucose (TyG) and atherogenic index of plasma (AIP) with stroke risk: findings from a nationwide prospective cohort

    Cohort study

  30. Diabetes Res Clin Pract

    Metabolic dysfunction-associated fatty liver disease and the risk of incident chronic kidney disease: A 10-year prospective cohort study

    Cohort study

  31. Diabetes Res Clin Pract

    Serum glycolipids mediate the link between dietary antioxidants and mortality in metabolic syndrome

    Cohort study

  32. Int J Obes (Lond)

    Association between metabolic signatures of predicted VAT mass and risk of MASLD and other chronic liver diseases

    Cohort study

  33. Cardiovasc Diabetol

    Association of the C-reactive protein–triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study

    Cohort study

  34. Diabetes Obes Metab

    Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials

    Meta-analysis

  35. Cardiovasc Diabetol

    Associations of cumulative exposure and dynamic trajectories of the triglyceride–total cholesterol–body weight index with new-onset cardiometabolic multimorbidity in middle-aged and older Chinese adults: evidence from a nationwide prospective cohort study

    Cohort study

  36. Pediatr Obes

    Metabolic Complications and Ultrasound‐Detected Liver Abnormalities in Paediatric Patients With Duchenne Muscular Dystrophy

    Cross-sectional study

  37. Cardiovasc Diabetol

    Association between triglyceride-glucose index and related indicators with heart failure–related mortality in individuals with early-stage cardiovascular-kidney-metabolic syndrome

    Cohort study

  38. Diabetes Obes Metab

    Body Roundness Index and All‐Cause Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Dual‐Cohort Study

    Cohort study

  39. Obesity (Silver Spring)

    Platelet‐Activating Factor Pathway in Women With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity

    Cross-sectional study

  40. Diabetes Obes Metab

    Proteomic Profiling of Plasma to Uncover Novel Intervention Targets and Prognostic Biomarkers for Chronic Liver Diseases

    Diagnostic or prognostic study

All 460 Briefs in ExploreShowing Briefs 41–80 of 460, newest first